
The New England Journal of Medicine | Research & Review Articles …
6 days ago · The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide …
Current Issue | New England Journal of Medicine
Explore the current issue of The New England Journal of Medicine (Vol. 393 No. 18).
Antibiotic Treatment for 7 versus 14 Days in Patients with …
Nov 20, 2024 · Bloodstream infections are associated with substantial morbidity and mortality. Early, appropriate antibiotic therapy is important, but the duration of treatment is uncertain. In …
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
Dec 11, 2024 · In a phase 3, open-label trial, we enrolled patients with ER-positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer that recurred or …
Lepodisiran - The New England Journal of Medicine
Mar 30, 2025 · Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease. The safety and efficacy of lepodisiran, an extended-duration, small …
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
Jun 1, 2025 · In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a …
Tirzepatide for Heart Failure with Preserved Ejection Fraction and ...
Nov 16, 2024 · Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and …
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based …
Jun 2, 2025 · Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell …
Remibrutinib in Chronic Spontaneous Urticaria | New England …
Mar 5, 2025 · Chronic spontaneous urticaria is an idiopathic syndrome defined by recurring itch, hives, or angioedema (or a combination of these symptoms) for more than 6 weeks. …
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
Apr 23, 2025 · In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression. Brensocatib, an oral, reversible inhibitor of dipeptidyl …